Selpercatinib Aimed atRET-Altered Cancers

2020/08/26 by Razelle Kurzrock · 15 citations
Medicine · #Lung Cancer Treatments and Mutations #Colorectal Cancer Treatments and Studies #Chronic Lymphocytic Leukemia Research

paper · doi:10.1056/nejme2024831

Abstract

A remarkable increase has occurred in the number of highly targeted drugs that have efficacy in patients with advanced cancers that harbor specific genomic alterations. Prime examples are the NTRK inhibitors that target NTRK fusions, which are found in only approximately 0.3% of cancers.1,2 As many as 75% of the patients with tumors that bear NTRK fusions and who have received these agents have had a response. These results have led to the Food and Drug Administration (FDA) approval of the use of the NTRK inhibitors larotrectinib and entrectinib in adult and pediatric patients with NTRK fusion–positive solid tumors, regardless . . .

Cited by

• Tumour-agnostic kinase inhibitors
• Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras
• In the literature: October 2020. [europepmc]
• Next-Generation Sequencing Enhances the Diagnosis Efficiency in Thyroid Nodules. [europepmc]
• Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer. [europepmc]
• Precision Oncology Targets in Biliary Tract Cancer. [europepmc]
• Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. [europepmc]
• Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload. [europepmc]
• Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancer. [europepmc]
• If it's a target, it's a pan-cancer target: Tissue is not the issue. [europepmc]
• Transcriptomic analysis of GITR and GITR ligand reveals cancer immune heterogeneity with implications for GITR targeting. [europepmc]
• Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives. [europepmc]
• If it is a solid tumor target, then it may be a hematologic cancer target: Bridging the great divide. [europepmc]
• Tumour-agnostic kinase inhibitors. [europepmc]
• Efficacy and safety of selpercatinib in treating RET-altered MTC: A single-arm meta-analysis☆ [europepmc]

Related

• Targeting RET in medullary thyroid cancer
• Repurposing approved drugs for cancer therapy
• Why targeted therapy hasn’t worked in advanced cancer
• Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum
• Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss—No Target Is Out of the Realm of Possibility